What we are watching
Top 10 by severity and recency
Approval and reimbursement watchlist
Checkpoint inhibitor label expansion, ADC class pricing, and CAR-T site-of-care policy are reshaping oncology economics.
Coverage and formulary decisions on PD-1/PD-L1 inhibitors across new tumor settings, antibody-drug conjugate pricing in HER2-low and triple-negative breast disease, and CAR-T outpatient site-of-care policy are in active rewrite across FDA, CMS, and the major commercial PBMs. AimwellBio's FDA, CMS LCD, and manufacturer-pipeline ingests are in calibration; full coverage activates on the next refresh cycle. Manufacturer commentary, MAC bulletins, and proposed-policy comment periods will populate this surface as each indexer comes online.
30 cancer-site stat facts under continuous tracking.
SEER is the foundational population-epidemiology layer for oncology decisions. AimwellBio integrates it directly into the signal pool.
The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute is the public ground-truth for U.S. cancer incidence, mortality, five-year relative survival, prevalence, and lifetime risk. AimwellBio pulls 30 site-level Cancer Stat Facts directly into the indication-aware indexer — with origin URLs, fetch timestamps, and reproducible claims for every fact.
Most oncology dashboards treat population data as a static appendix. AimwellBio treats it as a live signal class on equal footing with PubMed, SEC, and ClinicalTrials.gov. The cancers with the highest mortality and lowest survival — pancreatic, esophageal, liver, lung — should be where indication strategy starts, not where it ends up after the safer markets are picked.
Monitored issuers and operators
Volume & cadence of public disclosure
Methodology
This report is generated from a live ingest pipeline (tools/scout-ingest). Sources: ClinicalTrials.gov v2 API, PubMed E-utilities, SEC EDGAR, NCI SEER Cancer Stat Facts (live), with FDA openFDA, CMS Medicare Coverage Database, USPTO Patent Center, and manufacturer pipeline pages in calibration. Updated —. Every signal carries source URL and fetch timestamp; click any card to view origin.
Confidence framework. Source-backed > pattern-inferred > model-hypothesis > speculative. This report contains source-backed signals only. Pattern-inferred and model-hypothesis tiers are surfaced only inside member dashboards with explicit provenance flags.
SEER positioning. SEER provides free public NCI cancer-statistics data. AimwellBio adds adversarial verification, indication-aware filtering, and source-citation on top of the public layer. Premium linked datasets — SEER-Medicare, SEER-CAHPS, SEER-MHOS — are reserved for the paying tier when the question deserves them.
Limitations. This is a public, ToS-compliant view. Closed-source manufacturer disclosures, ministry tenders, and private regulatory correspondence are out of scope for this surface. Members access an extended view with partner intelligence subject to NDA. Sovereign-tagged institutions (KSA, GCC, MENA) reflect publicly observable regional headquarters; ministry-procurement detail is reserved for the partner intelligence surface.